The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An analysis of early molecular testing, time to treatment initiation, and medical resource use in metastatic NSCLC.
Craig H. Reynolds
Consultant or Advisory Role - Celgene; Pfizer
Honoraria - Celgene; Pfizer
David A. Smith
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Debra A. Patt
No relevant relationships to disclose
Gregory Smith
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Menaka Bhor
No relevant relationships to disclose
Ruslan Horblyuk
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Debra Rembert
Employment or Leadership Position - McKesson
Josephine A. Sollano
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Debajyoti Bhowmik
Employment or Leadership Position - McKesson
Jack Mardekian
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Mark Yap
Employment or Leadership Position - McKesson
Leonard Philip James
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer